Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis
Phase 3
Not yet recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Beijing VDJBio Co., LTD.
- Target Recruit Count
- 615
- Registration Number
- NCT06726096
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
Phase 2
Recruiting
- Conditions
- Idiopathic Multicentric Castleman's Disease
- Interventions
- Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kgBiological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kgBiological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Beijing VDJBio Co., LTD.
- Target Recruit Count
- 9
- Registration Number
- NCT05345522
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University First Hospital, Beijing, China
🇨🇳West China Hospital of Sichuan Hospital, Chengdu, China
Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Health Volunteer
- Interventions
- Biological: Placebo-2.5mg/kgBiological: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kgBiological: Placebo-7.5mg/kgBiological: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kgBiological: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kgBiological: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kgBiological: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kgBiological: Placebo-1mg/kgBiological: Placebo-5mg/kgBiological: Placebo-10mg/kg
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Beijing VDJBio Co., LTD.
- Target Recruit Count
- 46
- Registration Number
- NCT05256719
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Clinical Study of Single Dose IL-6R mAb Injection in RA Patients
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: IL-6R Monoclonal Antibody Injection 6mg/kgBiological: IL-6R Monoclonal Antibody Injection 8mg/kgBiological: IL-6R Monoclonal Antibody Injection 4mg/kgBiological: Tocilizumab Injection 8mg/kg
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Beijing VDJBio Co., LTD.
- Target Recruit Count
- 40
- Registration Number
- NCT05232396
- Locations
- 🇨🇳
Affiliated Hospital of Hebei University, Baoding, China
🇨🇳Peking University Shenzhen Hospital, Shenzhen, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
© Copyright 2025. All Rights Reserved by MedPath